BSX Boston Scientific
- Official Name: BOSTON SCIENTIFIC CORPORATION
- Headquarters: 300 Boston Scientific Way, MARLBOROUGH, MA, 01752-1234 US
- CEO: Michael F. Mahoney
- Website: bostonscientific.com
- Key Investor: BLACKROCK, INC | 9.58%
- Dedicated Investor: BOLLARD GROUP LLC | 54.28%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-16 | 1 | Won by 0.219 | 0.169 - (0.050) | ||
| 2025-07-23 | 2 | Lost by 0.660 | 3.983 - 4.643 | ||
| 2025-07-29 | 2R | Lost by 0.105 | 1.003 - 1.108 | ||
| 2025-07-30 | 3 | Lost by 1.300 | (0.105) - 1.195 | ||
| 2025-08-06 | 4 | Lost by 5.150 | (4.032) - 1.118 | ||
| 2025-08-07 | 1R | Won by 0.265 | 0.078 - (0.187) | ||
| 2025-08-13 | 5 | Lost by 0.628 | (0.513) - 0.115 | ||
| 2025-08-20 | 6 | Won by 1.320 | 3.214 - 1.894 | ||
| 2025-08-21 | 2R | Lost by 2.287 | (1.006) - 1.281 | ||
| 2025-08-27 | 7 | Lost by 2.799 | (0.168) - 2.631 | ||
| 2025-09-03 | 8 | Won by 1.575 TOTW | 1.713 - 0.138 | ||
| 2025-09-10 | 9 | Lost by 2.594 | (2.114) - 0.480 | ||
| 2025-09-17 | 10 | Lost by 5.920 | (5.060) - 0.860 | ||
| 2025-09-17 | 1R | Lost by 2.180 | (0.437) - 1.743 | ||
| 2025-09-24 | 11 | Won by 1.291 | (0.387) - (1.678) | ||
| 2025-10-01 | 12 | Won by 3.447 | (1.976) - (5.423) | ||
| 2025-10-08 | 13 | Won by 4.077 | 0.862 - (3.215) | ||
| 2025-10-15 | 14 | Won by 2.050 | 0.924 - (1.126) | ||
| 2025-10-22 | 15 | Won by 6.882 | 6.754 - (0.128) |
Latest News

Q3 Earnings Roundup: Boston Scientific (NYSE:BSX) And The Rest Of The Medical Devices & Supplies - Diversified Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are lo...

GE HealthCare to Acquire Intelerad for $2.3B to Boost Cloud Imaging
GEHC's $2.3B Intelerad deal aims to accelerate cloud imaging growth, expand outpatient reach and boost its shift toward high-margin SaaS revenue.

Defibrillator Market Competitive Landscape Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts
The global defibrillator market is forecasted to expand significantly, increasing from US$ 13.74 billion in 2024 to US$ 25.80 billion by 2033, with a ...

Okami raises $45M to commercialize vascular embolization devices
The company named former Inari Medical CEO Drew Hykes as its next leader in conjunction with the financing round.

BSX vs. EW: Which Heart Device Stock Is the Smarter Investment Now?
Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.

Should You Hold Quest Diagnostics Stock in Your Portfolio for Now?
DGX pushes growth through acquisitions and advanced diagnostics even as rising debt and tough competition pressure its outlook.

Boston Scientific (BSX): Evaluating Valuation as Investors Weigh Growth and Competitive Position
Boston Scientific (BSX) stock has been on the move recently, catching the attention of investors interested in healthcare innovation. With earnings mo...

Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)...

Boston Scientific (BSX) Down 5.7% Since Last Earnings Report: Can It Rebound?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Veeva Systems Stock Down Despite Q3 Earnings & Revenues Top Estimates
VEEV posts a Q3 earnings beat with stronger subscription growth and higher full-year guidance, highlighting continued momentum.

Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
Here is how Cencora (COR) and Boston Scientific (BSX) have performed compared to their sector so far this year.

LH Shares Gain Following Publication of New Plasma Detect MRD Data
Labcorp shares edge higher as new studies spotlight Plasma Detect's role in tracking MRD and improving post-surgery cancer detection.